Purpose Somatostatin-based radiopeptide treatment is generally performed using the β-emitting radionuclides 90 Y or 177 Lu. The present study aimed at comparing benefits and harms of both therapeutic approaches. 
Introduction
Neuroendocrine tumours are neoplasms arising from cells of the endocrine and nervous systems [1] . For differentiated neuroendocrine tumours, the therapeutic options include the multi-targeted tyrosine kinase inhibitor sunitinib [2] and the mTOR inhibitor everolimus [3] . For dedifferentiated tumours, the options include chemotherapy with streptozotocin, 5-fluorouracil and doxorubicin [4] . Importantly, most neuroendocrine tumours harbour subtypes of the somatostatin receptor family [5] , which permits treatment with the somatostatin analogue octreotide [6, 7] , imaging with radioactively labelled somatostatin analogues [8] and somatostatin receptor targeted radiopeptide treatment.
Somatostatin receptor targeted radiopeptide treatment with DOTA-TOC (tetraazacyclododecane tetraacetic acid modified Tyr 3 -octreotide, Fig. 1a ) was developed and brought into clinical use by our group in 1997 [9, 10] . Subsequently, it was established as an effective therapeutic option for the treatment of advanced neuroendocrine tumours [11] . DOTA-TOC is applied intravenously, is internalized into the tumour cell via the somatostatin receptor and irradiates the tumour with the β emission of the coupled radioisotope.
The radioisotopes commonly used for radiopeptide therapy are 90 Y and 177 Lu.
90
Y is a high-energy β emitter that can deliver high target doses. Its long emission range can penetrate to tissues further away from the target tissue. On the contrary, 177 Lu is a low-energy β emitter that transfers lower target doses. Its short emission range causes less irradiation of tissues further away from the target tissue. The availability of different radioisotopes potentially allows tailoring radiopeptide therapy to the individual patient.
The present study aimed to compare the efficacy and toxicity of somatostatin-based radiopeptide therapy with [ 90 Y-DOTA]-TOC versus [ 177 Lu-DOTA]-TOC in patients with progressive neuroendocrine tumours.
Materials and methods

Patients
Patients were included in the case of histologically confirmed neuroendocrine tumours, metastasized disease, progression within 1 year before enrolment and detectable tracer accumulation in the tumour in a somatostatin receptor scan. Patients were excluded in the case of concurrent anti-tumour treatment other than somatostatin treatment. Furthermore, patients were excluded in the case of pregnancy, breastfeeding, incontinence, haematological toxicities grade 3 or 4, or severe concomitant illness. Patients from Europe, Asia, North America and South America were enrolled. The study was designed and carried out according to good clinical practice, Swiss drug regulations and the Declaration of Helsinki. It was approved by the Basel Ethics Committee (Study number M120/97) and registered (Clinical Trials identifier: NCT00978211). Written informed consent was obtained from all patients.
Intervention DOTA-TOC was synthesized and radiolabelled according to Good Laboratory Practice (GLP) as previously described [12, 13] [11, 14, 15] .
Long-acting somatostatin analogues were withheld at least 6 weeks and short-acting somatostatin analogues were withheld at least 3 days before radiopeptide therapy. All treatment cycles were performed on an inpatient basis.
Based on the findings of our pilot study [14] , therapeutic cycles were repeated at an interval of at least 6 weeks in the presence of at least one of the following criteria: (1) stabilization or reduction in the summation of the longest widths of all pre-therapeutically identified lesions, (2) improvement in at least one of the five main symptoms: flush, diarrhoea, pain, fatigue and weight loss or (3) a detectable post-therapy marker decrease after a pre-therapy marker increase. The following markers were employed: hydroxyindoleacetic acid, angiotensinconverting enzyme, adrenocorticotropic hormone, alphafetoprotein, CA-125, CA-19.9, parathormone, calcitonin, carcinoembryonic antigen, chromogranin A, dopamine, gastrin, glucagon, noradrenaline, neuron-specific enolase, pancreatic polypeptide, proinsulin, serotonin and vasoactive intestinal peptide.
Intratherapeutic imaging
The biodistribution of DOTA-TOC was evaluated with planar whole-body scanning as previously described [11, 13, 16, 17] (Fig. 1b) . The maximum tracer accumulation in the tumour (tumour score ) and the kidneys (kidney score ) was visually scored by three board-certified nuclear medicine physicians blinded to the patient's baseline and follow-up data using a four-point scale: no tracer accumulation (score 0 ), tracer accumulation lower than in the liver (score 1), tracer accumulation similar to that in the liver (score 2) and tracer accumulation higher than that in the liver (score 3).
Follow-up
All patients were monitored prior to and for 3 days after injection of DOTA-TOC, and adverse events were continually logged. Following discharge, serum chemistry and haematological parameters were assessed biweekly for 10 weeks or until normalization of any pathological findings. The initial post-therapy morphological imaging was planned 6-8 weeks after treatment.
Additional DOTA-TOC cycles were suspended in the case of progression, permanent toxicity or loss of the ability or the willingness to travel to the treatment centre. At this time, follow-up was aimed at gathering data on survival and adverse events, including renal toxicity, until the patient's death. Follow-up information was gathered from the referring centres; family physicians and patients were contacted if further follow-up information was required. All follow-up information was centrally gathered and all individual cases were reviewed and checked for completeness at the study centre.
All toxicities were categorized in accordance with the Common Terminology Criteria for Adverse Events (CTCAE) v. 3.0 of the National Cancer Institute. Renal function was evaluated with the Modification of Diet in Renal Disease (MDRD) formula [18] ; renal adverse events were categorized in accordance with the guidelines of the National Kidney Foundation.
Statistical analysis
Primary endpoints were survival and severe renal toxicity. Severe renal toxicity was defined as toxicity grade 4 or 5 (glomerular filtration rate <30 or <15 ml/min per 1.73 m 2 ). Survival was evaluated from time of enrolment to death.
Survival predictors were evaluated using multivariable Cox regression with the subsequent pre-specified prognostic variables: gender, age, histology, duration of disease, prior surgery, prior chemotherapy, prior radiation, single lesion vs multiple lesions, liver lesions vs no liver lesions, bone lesions vs no bone lesions, tumour uptake score and treatment with [ Y are incorporated into the bone. We added each of these baseline variables in turn to our statistical model together with the corresponding interaction term with treatment group. In the case of any statistically significant interactions, we simultaneously added the significant interaction terms to the model in order to identify any independent interactions. Effect estimates were reported using hazard ratios (HR) with 95 % confidence intervals (CI).
The haematotoxicity rates for [ 177 Lu-DOTA]-TOC and [ 90 Y-DOTA]-TOC were compared employing logistic regression using the same set of co-variables as specified for the survival analyses.
In order to correctly identify predictors of renal adverse events the competing risk of death prior to renal adverse events was included into all analyses. Cumulative incidence functions were employed to identify the percentage of patients with renal adverse events or the competing event of death [20] and a Fine and Gray regression model for the subdistribution hazard [21] was established. The subsequent pre-specified cofactors were used for these calculations: gender, age, glomerular filtration rate at time of enrolment and allocation to [ Response evaluation using RECIST was established in 2000, 36 months after enrolment of the first patient [22] , and was not an a priori study outcome. In a supplementary analysis, all CT and MRI imaging results were revised to include all patients, in whom RECIST was applicable.
Further sensitivity analyses were performed to identify the effect of the year of treatment and the effect of all pre-specified co-variables on the 1-, 2-and 5-year survival, respectively. A two-sided p value of <0.05 was considered to indicate statistical significance. (Fig. 3b), solitary lesions (Fig. 3c) and extra-hepatic lesions (Fig. 3d) (Fig. 4) . No significant differences in effects were found in the subgroup of patients with bone lesions vs no bone lesions (Fig. 3e) . When all three significant interaction terms were simultaneously added to the statistical model, only the low tumour uptake effect remained close to statistical significance (p =0.09).
Results
Patients
Sensitivity analyses found no significant differences in survival after [ Y is able to induce high target doses. With its maximum range of 12 mm, it can deposit about 87 % of its energy in a 3-cm lesion; however, it can only deposit 63 % in a 1-cm lesion [23] . Conversely, the lower-energy β emitter The described subgroup effects meet the criteria for credible subgroup analyses [24] . Only a small number of a priori defined hypotheses were tested. All hypotheses were derived from a rationale developed in an animal model [19] . All subgroup variables are characteristics measured at baseline. The directions of the subgroup effects were defined a priori and assessed within one study. Large and significant effect sizes were found. As especially small solitary extra-hepatic metastases show low tumour uptake in the planar whole-body scan, a correlation of subgroup effects was found when simultaneously adding all significant interaction terms to the model.
Haematotoxicity is an acute toxicity that can be due to irradiation from [ Lu that is administered during treatment cycles and that integrates into the bone matrix [26] . The present study found higher rates of haematotoxicity after [ Lu-based radiopeptide therapy were available [11, 16, 17, 27] . There are several reasons why these studies commonly found lower kidney toxicity rates than reported in the present study. First, we allowed patients with reduced kidney function very close to severe renal toxicity who per se have a high likelihood of developing severe renal toxicity to be included. Second, the long follow-up period in many patients implicates an additional natural decrease in kidney function and a high possibility of nephrotoxic interventions after DOTA-TOC therapy. Third, our thorough follow-up until the patients' death was predisposed to detect decreased renal function. However, the cause for differences in renal toxicities found between each different study will remain widely unapparent. These differences, however, highlight the importance of increased comparative effectiveness research in radiopeptide therapy. In the present comparative study both treatment groups were followed up equally and the duration of follow-up was adequate to identify kidney toxicities that occur months after [ Strengths of the present study include the recruitment of 1,051 patients, allowing for powerful analyses, while the limited number of pre-specified co-variables in the regression model and the limited number of pre-specified subgroup analyses allowed the risk of overfitting and data-driven associations to be minimized. The single-centre design provided homogeneity of intervention among all patients. Advances in supportive care during the enrolment period of 9 years might have influenced the individual patient survival; however, no significant influence of the enrolment date on any of the described effects was found. Especially, the longer survival of [ a Estimates for all co-variables have been adjusted for histology as a categorical co-variable and for all further co-variables above adjusted for the relevant known prognostic co-variables, but unidentified factors might have been unbalanced between the treatment groups. Finally, although the present analysis meets current criteria for credible subgroup effects, our finding should be interpreted cautiously and confirmatory evidence is warranted.
In conclusion, this study compares survival and long-term toxicities of therapeutic regimens using the two most widely employed radioisotopes for radiopeptide therapy. Its results indicate longer survival for [ 
